Press release
-
Press Release
-
Press Release
Cision PR Newswire14 April 2026Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Read More » -
Press Release
-
Press Release
-
Press Release
-
Press Release